Keyword: Samsung

Roche is battling competition from Herceptin biosimilars and has reportedly sued Bioepis over its biosimilar as it heads for the finish line.

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.

Ahead of a big launch this fall, Biogen says it plans to increase its stake in a biosimilars joint venture shared with Samsung.

Novartis CEO Vas Narasimhan has joined the chorus calling for the U.S. to step up on biosimilar market access, stat.

AbbVie shielded Humira from another U.S. biosims threat in a deal that makes it "increasingly unlikely" any copycats will launch here before 2023.

New research takes a wide look at the strategy of "evergreening," or adding new patents to extend a drug's exclusivity.

Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.

Johnson & Johnson has successfully fended off most Remicade biosimilar competition, and it has a three-pronged strategy to thank.

J&J's Remicade is holding its own against a U.S. biosimilar rival—so much so, the company says, that it’s not worried about a second entrant.